Pathos AI Raises $237M at $3B Valuation to Expand AI Drug Discovery Platform
Pathos AI has secured $237 million in Series E funding led by Bristol Myers Squibb to accelerate its AI-driven drug development platform and clinical trial pipeline.
Biotechnology firm Pathos AI Inc. has secured $237 million in Series E funding, raising its market valuation to $3 billion. The round was led by pharmaceutical giant Bristol Myers Squibb Co., with participation from recurring investors including AstraZeneca plc, NEA, and General Atlantic, alongside several undisclosed backers. The capital injection will directly support the expansion of Pathos' artificial intelligence-driven oncology research and clinical trial management platform.
At the core of Pathos' operational model is Foundry, a proprietary software system engineered to optimize the discovery and development of cancer treatments. Foundry processes approximately 200 petabytes of oncological datasets in addition to real-time data produced by Pathos' own laboratory programs. By leveraging automated AI agents, the platform sifts through hundreds of potential drug candidate molecules to select the most viable options for therapeutic development. Beyond molecular selection, Foundry assists researchers in identifying specific patient demographics likely to respond to targeted therapies and helps design biomarker-driven clinical trial protocols.
Expanding Clinical Pipelines and Strategic Partnerships
Pathos plans to allocate its newly acquired capital toward advancing four primary drug development initiatives. The chief focus of these efforts is the company's JSKN016 program, which centers on constructing a novel cancer treatment using antibody-drug conjugates. This approach pairs therapeutic antigens with targeted antibodies to bind with malignant cells, triggering immune responses and directly delivering therapeutic agents to neutralize diseased tissue.
Another key focus within Pathos' pipeline is a collaborative project with AstraZeneca, an investor that initially backed the startup last year. The partnership centers on developing an ER PROTAC drug designed to exploit the natural material recycling mechanisms of human cells to combat cancerous growths.
Alongside its investment, Bristol Myers Squibb has formed a broader commercial partnership with Pathos and healthcare data firm Tempus AI Inc. Under a five-year agreement valued at $55 million, Pathos will license anonymized medical data from Tempus regarding patients with neurological conditions. Pathos will process these datasets through Foundry to gain deeper insights into underlying disease biology. Furthermore, Bristol Myers Squibb will receive access to both the Foundry platform and the newly acquired neurological data to refine its own clinical trials and optimize patient target selection.
What it means for developers
The integration of complex multi-petabyte datasets and automated decision-making agents inside platforms like Foundry underscores a broader movement across tech engineering: specialized AI architectures are moving from simple text generation toward orchestrating large-scale data analysis and domain-specific modeling.
Building modern AI applications requires engineering pipelines capable of interacting with advanced language models and automated agents. For software engineers building next-generation AI integrations, testing different model architectures is a critical step in system design. Developers looking to build or evaluate intelligent workflows can access top AI models cheaply through one unified API key at https://apixoai.online to streamline their prototyping and deployment processes.
In the domain of medical software engineering, Pathos' reliance on AI agents highlights growing opportunities for developers working on data ingestion, agentic orchestration, and privacy-compliant data processing. Integrating heterogeneous datasets—such as the 200 petabytes managed by Foundry or the anonymized neurological data supplied by Tempus AI—presents engineering challenges around scale, secure licensing workflows, and real-time inference. As pharmaceutical enterprises increasingly integrate AI software tools like Foundry into their regulatory and trial workflows, developer expertise in managing agentic pipelines and multi-modal data processing will remain crucial for the technology stack driving modern biotechnology.
Source: AI drug development startup Pathos AI closes $237M investment — SiliconANGLE AI. Written by the Apixo team from that report.
One key for Claude, GPT, GLM, DeepSeek and more. Pay per token with crypto.
Get your API key
